Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509509 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2NPC1LMNAPKMRAB9A | |
| SCHEMBL25324100 | 0.78 | CCR1 (0.48) | SMN1; SMN2 | |
| SCHEMBL30509522 | 0.76 | TDP1 (0.34) | SMN1; SMN2NPC1LMNAPKMRAB9A | |
| SCHEMBL25324022 | 0.76 | TDP1 (0.34) | SMN1; SMN2NPC1LMNAPKMRAB9A | |
| SCHEMBL25323906 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30509536 | 0.75 | HPGDS (0.40) | SMN1; SMN2NPC1LMNARAB9A | |
| SCHEMBL15885703 | 0.75 | HPGDS (0.40) | SMN1; SMN2NPC1LMNARAB9A | |
| SCHEMBL25323855 | 0.73 | CSNK1D (0.50) | — | |
| SCHEMBL19806360 | 0.71 | TGFBR1 (0.55) | — | |
| SCHEMBL29065492 | 0.70 | BRAF (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| EP-4214199-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-07-26 | — | — | EP | disclosed |
| CN-116490503-A | Casein kinase 1 delta modulators | 詹森药业有限公司 | 2023-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK2A1 | SMN1; SMN2 1386/4885NPC1 1692/4885LMNA 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.